FDA Asks Feedback on Tobacco Seller Training Info
Published Date: 2/25/2026
Notice
Summary
The FDA is asking for public feedback on their plan to keep collecting info about tobacco retailer training programs. These programs help stores teach employees the rules about selling tobacco safely and legally. If approved, this will continue without extra costs but keep the training standards clear and up-to-date. Comments are due by March 27, 2026, so retailers and the public can weigh in!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Time burden for retailer training records
The FDA estimates 237,113 retail establishments keep records for tobacco retailer training programs each year. FDA estimates one-time development for newly creating programs (18,969 establishments) totals 474,225 hours (25 hours per respondent for development activities) and annual recordkeeping totals 569,071 hours across establishments; FDA reports the total estimated annual hours changed from 2,183,780 to 1,043,296 hours, a decrease of 1,140,484 hours.
Guidance recommends tests, annual refreshers, 4-year records
FDA's guidance recommends retailers train employees on Federal tobacco sale rules, age verification, refusals, and other topics; require a written test before selling tobacco; provide refresher training at least annually; conduct internal compliance checks every 6 months; and retain training records for 4 years so they can show evidence during the 48-month civil money penalty period. Commenters and FDA say these recommendations are linked to preventing youth access to tobacco products.
Program remains voluntary; no FDA approvals now
FDA states the Tobacco Retailer Training Programs guidance is voluntary: retailers are not required to implement programs or submit them to FDA, and FDA will not recognize or approve existing training programs or certifications because it has not promulgated regulations establishing approved programs. FDA also states there are no capital or operating and maintenance costs associated with this information collection.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13140 — Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
2026-13139 — Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-13101 — Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorber
The FDA is officially classifying the medial knee implanted shock absorber as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative knee device faster and with confidence in its safety. The new classification is effective June 29, 2026, and could save time and money for makers and users alike.
Previous / Next Documents
Previous: 2026-03770 — Noise Exposure Map Notice: Louisville Muhammad Ali International Airport (SDF)
The FAA has officially approved the noise maps for Louisville Muhammad Ali International Airport, showing current and future noise levels around the airport. This means local communities and officials now have a clear picture of noise impact, helping guide future plans to keep neighborhoods peaceful. The approval took effect on February 23, 2026, and could lead to new steps to reduce noise and protect residents.
Next: 2026-03772 — Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice Regulations for Medicated Feeds
The FDA wants feedback on how medicated animal feed makers keep their records to make sure everything’s safe and up to date. This affects companies that produce medicated feeds, and they have until April 27, 2026, to share their thoughts. No big money changes yet, just a chance to improve how info is collected and stored.